Table 4 Comparison between patients with a residual PSA value at T2 < 1 ng/ml and > 1 ng/ml
– | Patients with PSA < 1 ng/ml at T2 (n = 12) | Patients with PSA > 1 ng/ml at T2 (n = 9) | All patients (n = 21) | p value |
|---|---|---|---|---|
Irretrievable lesions at T2 [n]: sum; mean | 49; 4.1 | 8; 0.9 | 57; 2.7 | 0.007 |
Irretrievable N and M [n]: sum; mean | 45; 3.8 | 6; 0.67 | 51 | 0.007 |
T2/T1 of PSMA-TV [%]: median (range) | 16.7 (0.0–63.5) | 52.0 (35.1–207) | 38.1 (0.0–207) | 0.008 |
T2/T1 of TL-PSMA [%]: median (range) | 6.2 (0.0–94.6) | 40.1 (6.0–268) | 11.4 (0.0–268) | 0.062 |
T2/T1 of summed miPSMA score [%]: median (range) | 29.7 (0.0–80.0) | 62.5 (16.7–100) | 37.5 (0.00–100) | 0.036 |
Downstaged patients at T2: sum; [%] | 8 [66.7%] | 3 [33.3%] | 11 [52.4%] | 0.198 |
Duration of ADT [days], median, range | 190 (98–289) | 116 (61–162) | 155 (61–289) | 0.002 |
PSA at T1 | 27.5 (2.5–107.0) | 32.9 (18.0–100.4) | 29.1 (107.0) | 0.925 |